1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Shuda Xia
Shuda Xia
Articles (127) 

Weekly Top Insider Buys Highlight for the Week of Oct. 13

The largest Insider Buys were for Reaves Utility Income Fund (UTG), CASI Pharmaceuticals Inc. (CASI), Vuzix Corporation (VUZI), and Avenue Therapeutics Inc. (ATXI)

October 14, 2017 | About:

The largest Insider Buys this week were for Reaves Utility Income Fund (UTG), CASI Pharmaceuticals Inc. (NASDAQ:CASI), Vuzix Corporation (NASDAQ:VUZI), and Avenue Therapeutics Inc. (NASDAQ:ATXI).

Reaves Utility Income Fund (UTG): Officer of Investment Advisor Ronald James Sorenson bought 6,102 shares

Officer of Investment Advisor Ronald James Sorenson bought 6,102 shares of UTG stock on Oct. 11 at the average price of $29.93. The price of the stock has increased by 3.27% since.

Reaves Utility Income Fund is an American investment advisor specializing in utilities and energy infrastructure. The company has approximately $2.7 billion in total assets under management as of June 30, 2017. The company’s research team averages over 20 years of industry experience. Portfolio managers evaluate research analysts' recommendations and determine priority and attractiveness in accordance with investment guidelines to maximize returns. The company has a market cap of $1.08 billion, and as of Oct. 13 it traded at $30.91.

On Oct. 13 Reaves Utility Income Fund announced today the next three monthly dividends at a rate of $0.16 per common share per month, unchanged from the per share rate paid for the previous financial quarter.

CASI Pharmaceuticals Inc. (NASDAQ:CASI): Director Wei-wu He bought 300,000 shares

Director Wei-wu He bought 100,000 shares of CASI stock on Oct. 10 at the average price of $1.95. The price of the stock has increased by 39.49% since.

CASI Pharmaceuticals Inc. is an American biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics focusing on cancer and other unmet medical needs. The company has a focus on China and the United States and has research and development operations in Beijing, China. The company has a market cap of $163.73 million, and as of Oct. 13 it traded at $2.72.

On Oct. 13 CASI Pharmaceuticals Inc. announced that it has entered into definitive agreements with certain institutional and accredited investors to purchase approximately $23.8 million of securities in a registered direct offering. The company expects to receive net proceeds of approximately $23.3 million after deducting agent’s fees and other offering expenses.

Vuzix Corporation (NASDAQ:VUZI): COO Paul A. Boris bought 5,000 shares

COO Paul A. Boris bought 5,000 shares of VUZI stock on Oct. 04 at the average price of $5.2. The price of the stock has increased by 6.73% since.

Vuzix Corporation is an American international technology firm that manufactures and sells computer display devices and software. The company also focuses on wearable display technology, including virtual reality and augmented reality devices. The company’s devices are used for mobile and augmented reality applications, such as 3D gaming, manufacturing training, and military tactical equipment. The company has a market cap of $123.07 million, and as of Oct. 13 it traded at $5.55.

On Oct. 11 Vuzix Corporation announced that its VIP Partner Upskill has released the next generation of Skylight Platform on the Vuzix M300 to enable faster and a broader adoption of augmented reality within its enterprises. The next generation of Skylight applies lessons learned over the 5 years that the product has been in market, and offers more scalable AR platform to support mass deployment of smart glasses across a global workforce.

Avenue Therapeutics Inc. (NASDAQ:ATXI): Director Lindsay A. Rosenwald bought 10,000 shares

Director Lindsay A. Rosenwald bought 10,000 shares of ATXI stock on Oct. 09 at the average price of $5.58. The price of the stock has decreased by 1.97% since.

Avenue Therapeutics Inc. is an American specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may provide less addiction potential than traditionally prescribed therapies and fill a gap in the acute pain market. The company is a subsidiary of Fortress Biotech Company. The company has a market cap of $54.92 million, and as of Oct. 13 it traded at $5.58.

On Sept. 27 Avenue Therapeutics Inc. announced that the first patient has been dosed in the pivotal Phase 3 clinical trial of IV tramadol for the management of pain following bunionectomy surgery. The Phase 3, randomized, double-blind, three-arm trial will evaluate the efficacy and safety of IV tramadol 50 milligram dosages and 25 milligram dosages versus a placebo.

For the complete list of stocks that were bought by their company executives, go to: Insider Trades.

Disclosure: I do not own stock in any of the companies mentioned in the article.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Shuda Xia


User Generated Screeners


pbarker46Begin here, Dividend Stocks
investrule1Large Cap Growth
Paapapop1
pbarker46Basic Materials
HOLKLSUTop 20 Rising Rates, Tax Refor
msubraFuture-Growth-20%+
msubraGrowth-20%+
msubraGrowth-12%+
Innerwestgame
investrule1P/S P/OCF Repair
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK